TScan Therapeutics, Inc. - Common Stock — Bilan (NASDAQ:TCRX) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Total de l'actif 188.11 M199.09 M272.15 M371.12 M228.79 M Total du passif 27.33 M99.66 M121.28 M130.15 M105.67 M Total des capitaux propres 160.78 M99.43 M150.87 M240.97 M123.12 M Total du passif et des capitaux propres 188.11 M199.09 M272.15 M371.12 M228.79 M Dette totale —29.29 M26.7 M32.07 M32.53 M Dette nette —29.29 M26.7 M32.07 M-119.87 M

Nouvelles

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

H.C. Wainwright réitère sa recommandation d’achat sur Tscan, objectif de 7$

TScan Therapeutics annonce la démission de son vice-président des finances

Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com

Le BPA de Tscan Therapeutics a dépassé les attentes de 0,09$, le CA a surpassé les prévisions

Tscan Therapeutics earnings beat by $0.09, revenue topped estimates

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan completes enrollment in trial cohort, receives FDA clearance

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates